canvuparatide
·Code: MBX 2109
canvuparatide: 1 clinical trial tracked.
canvuparatide evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about canvuparatide, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (1)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Followed by an Open-Label Extension to Evaluate the Safety and Efficacy of Canvuparatide (MBX 2109) in Adult Patients With Hypoparathyroidism
Primary endpoint: To evaluate the effect of pooled weekly doses of canvuparatide on the proportion of responder patients at week 26.
InterventionalRandomizedquadruple160 targetStarted 2026-08Completion 2029-0819 sites · United StatesMBX Biosciences